Navigation Links
Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
Date:5/23/2013

ATLANTA, May 23, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease treatments, announced today that it will present new results on its antiviral program to 'prevent' PML at an industry conference sponsored by the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, Roche and Biogen Idec).  JC polyomavirus (JCV) is the causative agent of Progressive Multifocal Leukoencephalopathy (PML). IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, can clear JC polyomavirus (JCV) infection in at least some patients and is active against the form of the virus that infects the majority of human beings. The Company will present preliminary outcomes of its proposed treatment to 'prevent' PML.  This oral medication, taken once or twice daily, is compatible with many different monoclonal antibody-based therapies and may offer a general solution to JCV infection as a companion therapeutic.

"JCV infection progresses to PML only in patients with chronic or drug-induced immune suppression. The ability to clear JCV infection in at least some patients is encouraging.  Further clinical evaluation confirming preliminary results is underway in several patient groups," said Milton H. Werner Ph.D., Chief Executive Officer and President of Inhibikase Therapeutics. 

About Inhibikase Therapeutics

Founded in 2008, Inhibikase Therapeutics is a private biopharmaceutical company developing novel, small-molecule compounds to treat bacterial, viral, fungal and parasitic diseases through a common mechanism of action, often involving a single drug.  Its pipeline of validated targets treat diseases therapeutically and prophylactically.  By inhibiting human pathways used by multiple bacteria and viruses for reproduction in the patient, the Company's compounds resolve infection with a lower likelihood of stimulating resistance. Inhibikase
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
2. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
3. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
4. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
7. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. Novelos Therapeutics Provides Product Pipeline Update
10. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
11. Mast Therapeutics Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... BOSTON , May 29, 2015 /PRNewswire/ ... custom automation, and contract manufacturing, and Vaxxas , ... drug delivery technology, have been named winners of the ... Nanopatch Jet Coating Instrument , an advanced technology platform ... development.  The award was announced last evening at the ...
(Date:5/29/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at the JMP Securities Life Sciences Conference in ... rd , 2015 at 11:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jmp27/hae ... a global healthcare company dedicated to providing innovative blood ...
(Date:5/29/2015)... -- Eli Lilly and Company (NYSE: LLY ) and ... have entered into a clinical trial collaboration to evaluate ... immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... The planned study will assess the combination as a ... The Phase I study is expected to establish the ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14
... U.S. Food and Drug Administration today advised consumers ... not to use the product. FDA warns that ... active pharmaceutical ingredient sibutramine, a prescription-only drug which ... the product label and could harm consumers, especially ...
... 8 Synapse Biomedical Inc ... U.S. Food and Drug Administration (FDA) designation of the ... Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis ( ... experiencing chronic hypoventilation and has now submitted for Humanitarian ...
Cached Medicine Technology:FDA: Potentially Harmful Stimulant Found in Slimming Beauty Capsules 2Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 2Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 3Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 4
(Date:5/29/2015)... 2015 A group of doctors have discovered ... national effort to teach this “new math” to children in ... been “sickened” by the recent implementation of Common Core Math ... it, Common Core is now a reality in children’s classrooms ... are now seeking ways to improve common core math training ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw ... the importance of proper sun protection. The print component ... a circulation of approximately 250,000 copies and an estimated ... nationally, through a vast social media strategy, and across ... To explore the digital version of the campaign, ...
(Date:5/29/2015)... 29, 2015 Healthpointe is now ... specialists, physical therapy, and injections , For patients ... and/or lower back pain, Healthpointe has a team ... herniated discs, disc protrusions and other causes of ... Healthpointe’s team of renowned surgeons are now treating ...
(Date:5/29/2015)... Chicago, IL (PRWEB) May 29, 2015 ... is giving patients a long-lasting impression on what ... provider of VisitandCare.com is on a mission to revolutionize ... cosmetic dentistry with a high-class Wellness & Spa. ... of the world’s most successful medical tourism agencies ...
(Date:5/29/2015)... May 29, 2015 As spring has ... Metro series outdoor saunas have increased in popularity as ... and work at summer cottages. While a perennial ... in summer projects a few weeks earlier than usual. ... with smaller lot sizes tend to prefer the Patio ...
Breaking Medicine News(10 mins):Health News:Doctors Discover a Cure for the Common Core 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2
... therapy (ECT) helps patients with severe depression who don't ... often in the earlier stages of the illness, ... ,"Electroconvulsive therapy has been shown to be ... persistent and severe depression, bipolar disorder, and schizophrenia," writes ...
... sudden outbreak of disease has claimed a tenth of Idahos ... fish food and labor. , The outbreak of ... in southwestern Idaho- the state Department of Fish and Game ... the region and official say that it probably resulted when ...
... Monday opposed introduction of sex education in Kashmir schools ... ,Addressing a media conference here, Asiya Andrabi, the DeM ... nefarious Indian designs to perpetuate obscenity and vulgarity in ... schools." ,Andrabi, branded as a hardliner, said ...
... in regard to doctor-patient ratio in various State Government ... varies from case to case depending upon various factors ... of patient-care required i.e. indoor/outdoor. According to the Medical ... works out to 1:1722. ,The patient ...
... company Advanced Cell Technology, is obviously thrilled with ... repair arteries and regenerate blood. , According to ... proceed on to hearts and arteries of ... have devised a straightforward way to make blood vessel precursor ...
... are 73557. There are 22273 numbers of doctors at ... on March 2006. As on 1.1.2007, total numbers of beds ... beds are available in urban government hospitals including Community Health ... of CHCs are located in government buildings. As on March ...
Cached Medicine News:Health News:Despite Being Effective Electroconvulsive Therapy is Underused for Severe Depression 2Health News:Disease Outbreak Claims Trout From Idaho Hatchery 2Health News:Hemangioblasts Aiding Eye Damage Repair 2
... Disc is a Hand Assisted Laparoscopic Surgery ... the surgeons hand may facilitate the procedure, ... has applications in colorectal, urological and general ... extracorporeal extension of pneumoperitoneum and abdominal access ...
... SleepStyle 200 series offers a range ... models. The design delivers therapy to ... features promote results in commercial and ... strongest differentiator in the SleepStyle 200 ...
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
... S6 Lightweight II CPAP has sound ... that maintains consistent pressure. The backlit ... the settings easy, and the interface ... adjustments is simple. This CPAP device ...
Medicine Products: